Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity
Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity
Prospective single arm study to evaluate a low-dose CT-based protocol for early detection of
 myocardial dysfunction in 50 cancer patients undergoing anthracycline-based chemotherapy.
Inclusion Criteria:

 1. Ability to understand and the willingness to sign a written informed consent.

 2. 18-75 year old patients with newly-diagnosed cancer scheduled to undergo
 anthracycline-based chemotherapy (minimum of 200 mg/m2 of doxorubicin or equivalent)
 at UCSD Medical Center.

 3. Women of child-bearing potential must agree to use adequate contraception (hormonal or
 barrier method of birth control; abstinence) prior to study entry, for the duration of
 study participation. Should a woman become pregnant or suspect she is pregnant while
 participating in this study, she should inform her treating physician immediately.

 • A woman of child-bearing potential is any female (regardless of sexual orientation,
 having undergone a tubal ligation, or remaining celibate by choice) who meets the
 following criteria:

 -  Has not undergone a hysterectomy or bilateral oophorectomy; or

 -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
 has had menses at any time in the preceding 12 consecutive months)

 4. Women of child-bearing potential must have a negative pregnancy test during the
 screening period.

 Exclusion Criteria:

 1. Prior chemotherapy with anthracycline;

 2. Persistent tachycardia (heart rate>90);

 3. LVEF<53% or history of cardiomyopathy or decompensated heart failure;

 4. Baseline GLS below lower limit of normal (normal range varies depending on age and
 gender (23)) or inability to obtain meaningful strain data due to poor quality of
 Echocardiographic images;

 5. Known unrevascularized coronary artery disease, myocardial infarction within 30 days
 of enrollment;

 6. Moderate or severe valvular heart disease;

 7. Prior allergy or intolerance to iodinated contrast;

 8. Renal failure (GFR<30, creatinine >1.5);

 9. Cancer involvement of the heart.